Next Article in Journal
Prospects and Challenges in the Development of Universal Influenza Vaccines
Previous Article in Journal
Porcine Parvovirus 7: Evolutionary Dynamics and Identification of Epitopes toward Vaccine Design
Open AccessCommunication

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth

1
The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
2
Los Alamo National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM 87545, USA
3
New Mexico Consortium, Los Alamos, NM 87545, USA
4
Moderna Inc., Cambridge, MA 02139, USA
5
International AIDS Vaccine Initiative-New York, New York, NY 10004, USA
6
Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(3), 360; https://doi.org/10.3390/vaccines8030360
Received: 5 June 2020 / Revised: 1 July 2020 / Accepted: 2 July 2020 / Published: 6 July 2020
(This article belongs to the Section HIV Vaccines)
A vaccine will likely be one of the key tools for ending the HIV-1/AIDS epidemic by preventing HIV-1 spread within uninfected populations and achieving a cure for people living with HIV-1. The currently prevailing view of the vaccine field is to introduce protective antibodies, nevertheless, a vaccine to be effective may need to harness protective T cells. We postulated that focusing a T-cell response on the most vulnerable regions of the HIV-1 proteome while maximizing a perfect match between the vaccine and circulating viruses will control HIV-1 replication. We currently use a combination of replication-deficient simian (chimpanzee) adenovirus and poxvirus modified vaccinia virus Ankara to deliver bivalent conserved-mosaic immunogens to human volunteers. Here, we exploit the mRNA platform by designing tetravalent immunogens designated as HIVconsvM, and demonstrate that mRNA formulated in lipid nanoparticles induces potent, broad and polyfunctional T-cell responses in a pre-clinical model. These results support optimization and further development of this vaccine strategy in experimental medicine trials in humans. View Full-Text
Keywords: HIV vaccine; HIVconsvX; HIVconsv; conserved regions; T cell vaccine; mRNA vaccines HIV vaccine; HIVconsvX; HIVconsv; conserved regions; T cell vaccine; mRNA vaccines
Show Figures

Figure 1

MDPI and ACS Style

Moyo, N.; Wee, E.G.; Korber, B.; Bahl, K.; Falcone, S.; Himansu, S.; Wong, A.L.; Dey, A.K.; Feinberg, M.; Hanke, T. Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. Vaccines 2020, 8, 360. https://doi.org/10.3390/vaccines8030360

AMA Style

Moyo N, Wee EG, Korber B, Bahl K, Falcone S, Himansu S, Wong AL, Dey AK, Feinberg M, Hanke T. Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. Vaccines. 2020; 8(3):360. https://doi.org/10.3390/vaccines8030360

Chicago/Turabian Style

Moyo, Nathifa; Wee, Edmund G.; Korber, Bette; Bahl, Kapil; Falcone, Samantha; Himansu, Sunny; Wong, Adrianne L.; Dey, Antu K.; Feinberg, Mark; Hanke, Tomáš. 2020. "Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth" Vaccines 8, no. 3: 360. https://doi.org/10.3390/vaccines8030360

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop